Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cardium agrees deal for commercialization of Excellagen in South Korea

Cardium Therapeutics : 09 January, 2012  (Company News)
Cardium Therapeutics is entering into the company's first international agreement for the commercialization of Excellagen in the South Korean market.
Cardium entered into a marketing and distribution agreement with BL and H, an established pharmaceutical company based in Korea, for the commercialization of Excellagen Formulated Fibrillar Collagen Gel in the South Korean market under a transfer price arrangement as further described below.



"With our successful regulatory clearance of Excellagen by the FDA, and production of commercial supplies in process, we look forward to initiating commercialization of Excellagen with strategic and distribution partners having access to podiatrists and other wound care specialists," said Christopher Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics. "In that regard, we are pleased to announce the first of what we plan to be a series of marketing and distribution agreements with commercialization partners in the USA and other markets consistent with Cardium's business model."    

             

Under the BL and H agreement, Cardium will manufacture and supply Excellagen to BL and H at an up-front transfer price which will be 40 percent of the sales price based on reimbursement pricing to be established for the South Korean market.  BL and H will be responsible for all costs related to regulatory filings, as well as sales, marketing and distribution activities. 



The Korea Food and Drug Administration registration process is adaptive to products that have received US FDA clearance and the registration and reimbursement pricing process can typically be completed within about a year from application.  As part of the regulatory process in Korea, BL and H plans to provide the health authorities with the findings of Cardium's Matrix clinical study, which showed that formulated collagen can significantly accelerate reductions in wound radius immediately following application compared to standard of care therapy in diabetic foot ulcers, and can support platelet activation and release of the wound healing protein, Platelet-Derived Growth Factor (PDGF). 
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo